Unanswered questions in acute myeloid leukaemia

The Lancet Oncology
F Ferrara

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous disease that presents with a range of morphological, cytogenetic, immunophenotypic, and biomolecular features. Over the past 20 years, application of new cytogenetic and molecular techniques has greatly improved knowledge of the pathophysiology of AML, resulting in new potential therapeutic applications. However, the results of current therapy are still unsatisfactory, especially in patients who have adverse prognostic factors at the time of diagnosis. Furthermore, some pivotal questions about the procedures of induction and postinduction therapy of AML remain unanswered, and substantial controversy exists on the optimum therapeutic approach for the disorder.

References

Feb 1, 1996·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M WatsonK Wheatley
May 20, 1998·Acta Haematologica·J F Bishop
May 15, 2002·Leukemia Research·Salvatore PalmieriFelicetto Ferrara

❮ Previous
Next ❯

Citations

May 16, 2013·Sensors·Nicola S FracchiollaAgostino Cortelezzi
Jan 6, 2012·Expert Opinion on Investigational Drugs·Felicetto Ferrara
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Felicetto Ferrara
Dec 27, 2011·The Lancet Oncology·Felicetto Ferrara
Mar 21, 2007·Critical Reviews in Oncology/hematology·Susan D P W M de Jonge-PeetersEdo Vellenga
Jun 30, 2009·American Journal of Hematology·Felicetto FerraraFabrizio Pane
Nov 13, 2007·Critical Reviews in Oncology/hematology·Felicetto FerraraFranco Leoni
Oct 8, 2005·Seminars in Oncology·Valter GatteiMichele Maio
Feb 23, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felicetto FerraraSalvatore Palmieri
Apr 2, 2011·Clinical Lymphoma, Myeloma & Leukemia·Felicetto Ferrara
Aug 22, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felicetto FerraraFabrizio Pane
Mar 17, 2007·Hematological Oncology·Felicetto FerraraSalvatore Palmieri
May 12, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PalmieriF Ferrara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

© 2022 Meta ULC. All rights reserved